These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39121598)

  • 21. Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients.
    Torgauten HM; Onyango TB; Ljostveit S; Hallin EI; Serkland TT; Skrede S; Langeland N; Cox RJ; Wergeland S; Myhr KM; Torkildsen Ø
    Mult Scler Relat Disord; 2024 Sep; 89():105770. PubMed ID: 39029342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
    Hay M; Rollot F; Casey R; Kerbrat A; Edan G; Mathey G; Labauge P; De Sèze J; Vukusic S; Laplaud DA; Papeix C; Moreau T; Thouvenot E; Defer G; Lebrun-Frénay C; Ciron J; Berger E; Stankoff B; Clavelou P; Maillart E; Heinzlef O; Zéphir H; Ruet A; Casez O; Moulin S; Al-Khedr A; Bourre B; Pelletier J; Magy L; Neau JP; Camdessanché JP; Doghri I; Wahab A; Tchikviladzé M; Labeyrie C; Hankiewicz K; Le Page E; Michel L;
    Neurology; 2024 Oct; 103(8):e209886. PubMed ID: 39321406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
    Houtchens M; Howard D
    Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A; Cárdenas-Robledo S; Tagliani P; Arrambide G; Otero-Romero S; Carbonell-Mirabent P; Rodriguez-Barranco M; Rodríguez-Acevedo B; Restrepo Vera JL; Resina-Salles M; Midaglia L; Vidal-Jordana A; Río J; Galan I; Castillo J; Cobo-Calvo Á; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Eur J Neurol; 2021 Oct; 28(10):3384-3395. PubMed ID: 33340215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
    Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
    Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of SARS-CoV-2 Infection in Unvaccinated Multiple Sclerosis Patients on Disease-Modifying Therapies.
    Al-Shammri S; Chadha G; Chattopadhyay A; Doi S
    Med Princ Pract; 2023; 32(2):143-148. PubMed ID: 37231972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
    Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Spelman T; Forsberg L; McKay K; Glaser A; Hillert J
    Mult Scler; 2022 Jun; 28(7):1051-1059. PubMed ID: 34212816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.
    Seery N; Li V; Nguyen AL; Roos I; Buzzard KA; Atvars R; Taylor N; Tunnell K; Carey J; Dwyer C; Taylor HFL; Baker J; Marriott MP; Kilpatrick TJ; Kalincik T; Monif M
    Mult Scler Relat Disord; 2020 Nov; 46():102516. PubMed ID: 32957057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo.
    Komoni E; Jashari F; Boshnjaku D; Myftiu B; Pushka M; Blyta A; Nallbani-Komoni R
    Med Sci Monit; 2024 Jan; 30():e942992. PubMed ID: 38287659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
    Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?
    Immovilli P; Schiavetti I; Franceschini A; De Mitri P; Gelati L; Rota E; Guidetti D
    Mult Scler Relat Disord; 2024 May; 85():105547. PubMed ID: 38518506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
    Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
    Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia.
    Alshamrani F; Alnajashi H; AlJumah M; Almuaigel M; Almalik Y; Makkawi S; Alsalman S; Almejally M; Qureshi S; Aljarallah S; AlKhawajah N; Kedah H; Alotaibi H; Saeedi J; Alamri A
    Mult Scler Relat Disord; 2021 Jul; 52():103004. PubMed ID: 34049217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    Chaudhry F; Bulka H; Rathnam AS; Said OM; Lin J; Lorigan H; Bernitsas E; Rube J; Korzeniewski SJ; Memon AB; Levy PD; Schultz L; Javed A; Lisak R; Cerghet M
    J Neurol Sci; 2020 Nov; 418():117147. PubMed ID: 32980780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.